Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Adaptive Biotechnologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Adaptive Biotechnologies's regulatory disclosures and financial reporting.
Adaptive Biotechnologies Corp (symbol ADPT) received a Rule 144 notice from director Katherine E. Owen covering a planned sale of up to 9,615 shares of common stock. The shares are associated with restricted stock awards granted in 2022, 2023, and 2025 and are to be sold through Morgan Stanley Smith Barney LLC. The filing reports an aggregate market value of approximately $249,990 for the shares, with an approximate sale date of August 26, 2026 on NASDAQ.
Adaptive Biotechnologies Corp (ADPT) reports that former officer Harlan Robins plans to sell up to 402160 shares of common stock through Goldman Sachs & Co. LLC under Rule 144, with an aggregate market value of 10230950.4. These shares were acquired on 03/04/2022 as compensation via stock options and are designated for a cashless exercise / same-day sale. The notice also lists multiple prior open-market sales of Adaptive Biotechnologies common stock by Robins during the past three months.
Adaptive Biotechnologies Corp (ADPT) director Robert Hershberg reported an option exercise and related share sales. On 2026-08-18, he exercised a stock option for 15,000 shares of common stock at an exercise price of $6.32 per share, fully using an option that would have expired on October 18, 2026. He then sold 30,664 shares of common stock in two transactions at weighted average prices of $24.39 and $24.41 per share, with actual sale prices ranging from $24.38–$24.44 as disclosed in the footnotes.
Adaptive Biotechnologies Corp (ADPT) reported insider transactions by CEO and Chairman Chad M. Robins involving an exercise-and-sell pattern over two days. On August 17 and 18, 2026, Robins exercised stock options for a total of 600,000 shares of common stock at an exercise price of $6.55 per share. He then sold 600,000 shares of common stock in multiple open-market transactions at weighted average prices around $24–$26 per share, as described in the price-range footnotes. The options exercised were fully vested and would have expired on February 7, 2028.
Adaptive Biotechnologies Corp (ADPT) director Peter M. Neupert reported an option exercise and significant share sales. He exercised 15,000 stock options for Common Stock at an exercise price of $6.32 per share, fully exhausting that option grant. On the same date, he sold an aggregate 124,690 shares of Common Stock in open-market transactions at weighted average prices around $25.10–$25.27 per share, as detailed in price-range footnotes.
Adaptive Biotechnologies Corporation (symbol ADPT) reports that former officer Harlan Robins plans to sell up to 215,632 shares of common stock under Rule 144 through Goldman Sachs & Co. LLC. The filing lists an aggregate market value for these planned sales of $5,496,459.68 and states that there were 159,595,842 shares of common stock outstanding. The securities to be sold were acquired on 03/04/2022 as compensation via stock options, with the planned disposition described as a compensation-related cashless exercise and same-day sale. The notice also details multiple prior sales of ADPT common stock by Robins over the past three months, each with specific share amounts, dates, and dollar values.
Adaptive Biotechnologies Corporation (ADPT) director Robert M. Hershberg filed a notice of proposed resale under Rule 144. The filing covers up to 30,664 shares of common stock to be sold through Morgan Stanley Smith Barney, with an aggregate market value of $748,303.36. The calculation references 159,595,842 shares outstanding as of August 18, 2026, and includes shares from stock option exercises and restricted stock.
Adaptive Biotechnologies Corp (ADPT) insider Chad Robins has filed a notice of proposed sale of common stock under Rule 144. He plans to sell 278,676 shares through Goldman Sachs & Co. LLC via a cashless exercise/same-day sale of stock options originally granted on February 7, 2018. The planned sale represents part of an issuer share base of 159,595,842 shares outstanding. Over the prior three months, Robins has already sold 321,324 shares of common stock.
Adaptive Biotechnologies Corp (ADPT) received a notice that former officer Harlan Robins intends to sell shares of its common stock under Rule 144. The planned sale covers 261,044 shares, with an indicated aggregate market value of $6,411,240.64. Shares outstanding were listed as 159,595,842 as of 08/18/2026; this is a baseline figure, not the amount being sold.
The shares to be sold were originally acquired on 02/07/2019 as stock option compensation, with the planned transaction described as a cashless exercise / same-day sale through Goldman Sachs & Co. LLC. The notice also lists multiple prior common stock sales by Harlan Robins in the preceding three months, including blocks of 250,000 shares on 07/02/2026 and 207,600 shares plus 284,800 shares on 07/21/2026.
For ticker ADPT, Harlan Robins filed a notice of intent to sell 300,992 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $7,455,571.84, in transactions expected on or after 08/17/2026.
The shares to be sold include stock acquired as performance awards on 03/10/2026 and through stock options granted 02/07/2019, including a cashless exercise/same‑day sale component. The filing also lists multiple prior common stock sales by Robins during June and July 2026.